RhumbLine Advisers
VOR icon

RhumbLine Advisers’s Vor Biopharma VOR Stock Holding History

RhumbLine Advisers’s Portfolio VOR Stock Details VOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.09M Sell
56,994
-534
-0.9% -$11.4K ﹤0.01% 2222
2026
Q2 		$1.06M Buy
+57,528
New +$870K ﹤0.01% 2283
2024
Q3 		– Sell
-275
Closed -$5.5K – 4337
2024
Q2 		$5.5K Sell
275
-1,909
-87% -$61.7K ﹤0.01% 4072
2024
Q1 		$103K Buy
2,184
+34
+2% +$1.49K ﹤0.01% 3438
2023
Q4 		$96.7K Sell
2,150
-95
-4% -$3.92K ﹤0.01% 3459
2023
Q3 		$95.2K Buy
2,245
+114
+5% +$6.18K ﹤0.01% 3478
2023
Q2 		$132K Buy
+2,131
New +$195K ﹤0.01% 3422
2022
Q2 		– Sell
-817
Closed -$99K – 3245
2022
Q1 		$99K Sell
817
-100
-11% -$17K ﹤0.01% 2887
2021
Q4 		$213K Buy
917
+147
+19% +$42.4K ﹤0.01% 2818
2021
Q3 		$242K Buy
770
+193
+33% +$57.4K ﹤0.01% 2846
2021
Q2 		$215K Buy
577
+97
+20% +$47.9K ﹤0.01% 2907
2021
Q1 		$414K Buy
+480
New +$406K ﹤0.01% 2573

Other funds holding VOR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Nan Fung Trinity
Nan Fung Trinity Central, Hong Kong, Hong Kong $1.04B AUM 32.17% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
ALPS Advisors
ALPS Advisors Denver, Colorado $21.8B AUM 17.58% 1-Year Est. Return
Johnson & Johnson
Johnson & Johnson New Brunswick, New Jersey $762M AUM 69.66% 1-Year Est. Return
STRS Ohio
STRS Ohio Columbus, Ohio $27.1B AUM 34.64% 1-Year Est. Return

RhumbLine Advisers's VOR Position: Q3 2026 in Review

RhumbLine Advisers reduced its Vor Biopharma (VOR) stake by 0.93% in Q3 2026, selling an estimated $11.4K and leaving 56,994 shares worth $1.09M. The position accounts for ﹤0.01% of the portfolio, ranked #2222.

RhumbLine Advisers first reported a position in VOR in Q1 2021 and has held it in 12 quarters since. 62 funds tracked by Wall St. Rank hold VOR as of Q3 2026.

  • RhumbLine Advisers held 56,994 shares of Vor Biopharma worth $1.09M as of Q3 2026.
  • RhumbLine Advisers sold 534 Vor Biopharma shares in Q3 2026, an estimated $11.4K.
  • Vor Biopharma made up ﹤0.01% of RhumbLine Advisers's portfolio in Q3 2026, its #2222 holding.
  • RhumbLine Advisers first reported a position in Vor Biopharma in Q1 2021 and has held it in 12 quarters since.
  • 62 funds tracked by Wall St. Rank held Vor Biopharma as of Q3 2026.

Based on RhumbLine Advisers's 13F filing for Q3 2026, filed 10 Nov 2026.